

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nenocorilant,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Details : CORT125236 (Nenocorilant) is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : CORT125236
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2025
Lead Product(s) : Nenocorilant,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
